Spinal Muscular Atrophy Clinical Trial
Official title:
Aerobic Training Improves Oxidative Capacity, But Not Function in Spinal Muscular Atrophy III
Spinal muscular atrophy type III, (SMAIII) is a disease in the nerve cells in the spinal
cord which leads to to progressive muscle weakness and atrophy. No effective treatment is
available for SMA. We have previously shown that patients with muscular dystrophies improve
oxidative capacity (VO2max), muscle strength and daily function by aerobic conditioning.
Patients with SMAIII share many clinical features with these conditions, although the
mechanism of muscle weakness is different. In this study, we investigated how patients with
SMAIII respond to aerobic training.
6 patients and 9 healthy age- and sex-matched controls completed a 12 weeks training
program. Subjects performed a total of 42 training session of 30 min on a stationary cycle
ergometer at home. The work intensity was moderate and set to match a target heart rate.
Training induced an increase without inducing muscle damage. However, training-induced
fatigue was a major complaint in all patients, and caused one patient to drop out, increased
the need for sleep in three patients and two had to modify the training program.
The fatigue limits the use of this therapy. The training-induced fatigue, which is not
encountered in muscle diseases, warrants investigations into alternative training methods to
improve quality of life in patients with SMAIII.
Spinal muscular atrophy type III, (SMAIII) is a recessively inherited disease in the lower
motor neuron in the anterior horn of spinal cord leading to to progressive muscle weakness
and atrophy. Currently there is no effective treatment available for SMA. We have previously
shown that patients with muscular dystrophies improve oxidative capacity (VO2max), muscle
strength and daily function by aerobic conditioning. Patients with SMAIII share many
clinical features with these conditions, although the mechanism of muscle weakness is
different. In this study, we investigated how patients with SMAIII respond to aerobic
training.
6 patients and 9 healthy age- and sex-matched controls completed a 12 weeks training
program. Subjects performed a total of 42 training session of 30 min on a stationary cycle
ergometer at home. The work intensity was moderate and set to match a target heart rate.
VO2max was measured during a incremental exercise test using indirect calorimetry before and
after the training period. Functional tests adressing patients walking and stair climbing
abilities, were performed before and after the training period. Changes in activities of
daily living was adressed in a standardized questionnaire after the training period.
Training induced an increase without inducing muscle damage. There were no changes in
patients' functional capacities. However, training-induced fatigue was a major complaint in
all patients, and caused one patient to drop out, increased the need for sleep in three
patients and two had to modify the training program.
The fatigue limits the use of this therapy. The training-induced fatigue, which is not
encountered in muscle diseases, warrants investigations into alternative training methods to
improve quality of life in patients with SMAIII.
;
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04851873 -
Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA)
|
Phase 3 | |
Completed |
NCT03223051 -
Development of a Space Exploration Assessment for Children With Spinal Muscular Atrophy
|
N/A | |
Completed |
NCT04335942 -
Characterization of the Postural Habits of Wheelchair Users Analysis of the Acceptability of International Recommendations in the Prevention of Pressure Sores Risk by Using a Connected Textile Sensor
|
N/A | |
Recruiting |
NCT05794139 -
Safety and Efficacy of NMD670 in Ambulatory Adult Patients With Type 3 Spinal Muscular Atrophy
|
Phase 2 | |
Not yet recruiting |
NCT06300996 -
Spinal Cord Stimulation for the Treatment of Motor Deficits in People With Spinal Muscular Atrophy - Upper Limb
|
N/A | |
Not yet recruiting |
NCT00961103 -
Motor Development and Orthoses in Spinal Muscular Atrophy (SMA)
|
N/A | |
Completed |
NCT00227266 -
Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy
|
Phase 2 | |
Completed |
NCT00374075 -
Study of Safety and Dosing Effect on SMN Levels of Valproic Acid (VPA) in Patients With Spinal Muscular Atrophy
|
Phase 1 | |
Enrolling by invitation |
NCT05539456 -
Reliability and Validity of the Turkish Version of the PedsQL 3.0 Neuromuscular Module for 2-to 4- Year-old
|
||
Recruiting |
NCT05779956 -
Personalized Medicine for SMA: a Translational Project
|
||
Recruiting |
NCT03217578 -
Neonatal Spinal Muscular Atrophy (SMA) Screening
|
||
Recruiting |
NCT03300869 -
Natural History of Types 2 and 3 SMA in Taiwan
|
||
Completed |
NCT01703988 -
An Open-label Safety, Tolerability and Dose-Range Finding Study of Multiple Doses of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy
|
Phase 1/Phase 2 | |
Withdrawn |
NCT02235090 -
Study of Feasibility to Reliably Measure Functional Abilities' Changes in Nonambulant Neuromuscular Patients Without Trial Site Visiting
|
N/A | |
Completed |
NCT02123186 -
Newborn Screening for Spinal Muscular Atrophy
|
N/A | |
Completed |
NCT00756821 -
A Pilot Study of Biomarkers for Spinal Muscular Atrophy
|
N/A | |
Completed |
NCT00004771 -
Phase II Study of Leuprolide and Testosterone for Men With Kennedy's Disease or Other Motor Neuron Disease
|
Phase 2 | |
Recruiting |
NCT05366465 -
Quality of Life and Participation of the Adult With Spinal Muscular Atrophy in France
|
||
Recruiting |
NCT06310421 -
Spinal Muscular Atrophy Neonatal Screening Program
|
||
Enrolling by invitation |
NCT03655223 -
Early Check: Expanded Screening in Newborns
|